Contact Us

Compassionate Use Statement
Syntimmune has determined that none of our investigational drugs are suitable for compassionate use under any circumstances at this time. We will periodically reevaluate this policy as our clinical development programs advance.

CONTACTS

Media Contact:  Adam Hansard, adam.hansard@syntimmune.com

Investor Relations:  Nicole Luosey, nicole.luosey@syntimmune.com